Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MEIP 
MEI Pharma Inc (MEIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MEIP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.51% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.33M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 7949 | Beta 0.63 | 52 Weeks Range 2.15 - 4.10 | Updated Date 04/2/2025 |
52 Weeks Range 2.15 - 4.10 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.68% | Return on Equity (TTM) -93.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -24019858 | Price to Sales(TTM) 0.27 |
Enterprise Value -24019858 | Price to Sales(TTM) 0.27 | ||
Enterprise Value to Revenue 1.39 | Enterprise Value to EBITDA -1.58 | Shares Outstanding 6662860 | Shares Floating 4938576 |
Shares Outstanding 6662860 | Shares Floating 4938576 | ||
Percent Insiders 1.31 | Percent Institutions 40.69 |
Analyst Ratings
Rating 3 | Target Price 20 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MEI Pharma Inc
Company Overview
History and Background
MEI Pharma, Inc. is a pharmaceutical company focused on the development of cancer therapeutics. Founded in 2000, it has evolved from a preclinical research firm to a clinical-stage company with multiple drug candidates.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing novel therapies for cancer, including hematologic malignancies and solid tumors. The company's primary focus is on clinical-stage drug candidates.
Leadership and Structure
MEI Pharma is led by an executive team with experience in pharmaceutical development and commercialization. The organizational structure is typical of a clinical-stage biotech company.
Top Products and Market Share
Key Offerings
- Voruciclib: A CDK9 inhibitor currently in clinical development for hematologic malignancies. Market share is currently nonexistent as the drug is not yet approved. Competitors include companies developing other CDK inhibitors.
- ME-344: An isoflavone-derived mitochondrial inhibitor also in clinical development for solid tumors. Market share is currently nonexistent as the drug is not yet approved. Competitors include companies developing mitochondrial inhibitors.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The oncology segment is a major area of focus.
Positioning
MEI Pharma is positioned as a clinical-stage biopharmaceutical company focusing on targeted therapies for cancer. Its competitive advantage relies on the novelty and efficacy of its drug candidates.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. MEI Pharma's position within this TAM depends on the successful development and commercialization of its drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Targeted therapies
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercial infrastructure
- High risk of drug failure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- FDA approval of drug candidates
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- GILD
- BIIB
- MRK
Competitive Landscape
MEI Pharma faces intense competition from established pharmaceutical companies with greater resources and larger market share. Its success depends on the differentiation and efficacy of its drug candidates.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: MEI Pharma's growth has been dependent on the progress of its clinical trials and partnerships.
Future Projections: Future growth is contingent on successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for Voruciclib and ME-344, and pursuing potential partnerships.
Summary
MEI Pharma is a clinical-stage biopharmaceutical company with promising cancer therapies in development. Its success hinges on clinical trial results and strategic partnerships. The company faces significant competition and financial challenges, making it a high-risk, high-reward investment. Its growth trajectory depends on advancing its pipeline and securing regulatory approvals. Continued monitoring of clinical trial progress and market dynamics is essential.
Similar Companies
BIIB
Biogen Inc
BIIB
Biogen Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The data provided may not be exhaustive or completely accurate. Investments in pharmaceutical companies are inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MEI Pharma Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2003-12-19 | Acting CEO, CFO & Corporate Secretary Mr. Justin J. File CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://meipharma.com |
Full time employees 28 | Website https://meipharma.com | ||
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.